[15] This is the study we'll focus on, but the other studies cited above can be read for more background
Were here to provide answers to all your questions.
A separate analysis done at Virginia Commonwealth University of more than 841,000 patients with stage 1, 2, or 3 breast cancer, also showed that at five and 10 years after treatment, the women who had been taking GLP-1 drugs had a stunning 60% lower death rate from any cause compared to non-GLP-1 users
Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, has demonstrated cardiovascular benefits that extend beyond weight loss alone
Wegovy, however, demonstrated impressive weight reduction outcomes during clinical trials, leading to strong adoption across multiple markets